Skip to content

A Clinical Trial for the Evaluation of the Efficacy and Safety of MED-01 on Vaginal Health

A 12 week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of MED-01 on Vaginal Health

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005881
Enrollment
100
Registered
2021-02-09
Start date
2020-12-23
Completion date
Unknown
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Intervention group: MED-01 probiotics 500mg capsule once a day Placebo group: placebo 500mg capsule once a day

Sponsors

Mediogen
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Women of childbearing age over 19 years of age and under 50 years of age 2) A person with a score of 4-6 on the Nugent core. 3) A person who agrees to participate in the human application test before the human application test begins and has prepared the written consent form.

Exclusion criteria

Exclusion criteria: 1) Those who are currently being treated for severe cardiovascular system, immune system, respiratory system, gastrointestinal tract/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease and malignant tumor (however, considering the condition of the human subject You can participate in the test at the discretion of the tester.) 2) The subjects who treated for vaginal or urinary tract infection as of Visit 1 3) The subjects with vaginal bleeding, abnormal vaginal secretion, or urinary system abnormality as of the standard of Visit1 4) The subjects who has been given antibiotics, antibacterial agents, steroids, and immunosuppressants within two weeks of visiting1 5) The subjects who has ingested health functional foods, probiotics, and lactobacillus products continuously (more than four times a week) within two weeks of visiting 1 6) A person who has received acupuncture treatment for women's cleanser, vaginal cleanser, sedentary treatment and vaginal health within one week of visiting 1 7) The subjects with unregulated hypertension (measuring standard after 10 minutes stabilization of the person subject to human application test) (above 160mmHg of blood pressure in the retractor or 100mmHg of blood pressure in the retractor). 8) Unregulated diabetics (if HbA1C exceeds 6.5%) 9) The subjects whose creatine is more than twice the normal limit of the testing agency 10) The subjects whose AST (GOT) or ALT (GPT) is at least three times the normal limit of the testing agency 11) The subjects whose TSH is less than 0.1 UU/ml or greater than 10 µU/ml 12) The subjects who are sensitive or allergic to the ingredients of this human-applied test food; 13) The subjects who is pregnant, breast-feeding, or planning to conceive within three months. 14) The subjects who has participated in another interventional clinical trial (including a human application test) within one month of the commencement of this human application test or who has a plan to participate in another interventional clinical trial (including a human application test) after the commencement of this human application test. 15) The subjects who is deemed inappropriate by the human application test testers for this human application test.

Design outcomes

Primary

MeasureTime frame
Nugent Score

Secondary

MeasureTime frame
Vaginal pH;Vaginal microflora;Symptom Survey Assessment

Countries

Korea, Republic of

Contacts

Public Contactsungtaek park

Hallym University Medical Center-Kangnam

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026